1 – 8 of 8
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors : a multicenter IMWG study
(
- Contribution to journal › Article
- 2016
-
Mark
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009
(
- Contribution to journal › Article
-
Mark
Management of relapsed multiple myeloma: Recommendations of the international myeloma working group.
(
- Contribution to journal › Scientific review
- 2015
-
Mark
Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
(
- Contribution to journal › Article
- 2014
-
Mark
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
(
- Contribution to journal › Scientific review
- 2009
-
Mark
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: A population-based study
2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.0391-0391(
- Contribution to journal › Published meeting abstract
-
Mark
Impaired Stem Cell Mobilization by Fludarabine in MM: Results from a Randomized Phase II Trial
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity
2008) 13th Congress of the European-Hematology-Association In Haematologica-The Hematology Journal 93. p.0209-0209(
- Contribution to journal › Published meeting abstract